Drug intelligence / Profile preview

ethylenediamine diaceturate

Development stage
Unknown
Lead developer
Jinzhou Ahon Pharmaceutical
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Ethylenediamine diaceturate (also known as diacetylaminoacetic acid ethylenediamine) is a small molecule hemostatic agent developed and approved in China. It is primarily used for the prevention and treatment of various types of bleeding, including surgical bleeding, gastrointestinal hemorrhage, cerebral hemorrhage, gynecological hemorrhage, epistaxis, and hematuria. The drug's mechanism of action involves the inhibition of plasminogen activators, which prevents the conversion of plasminogen to plasmin, thereby inhibiting fibrinolysis and promoting clot stability. Additionally, ethylenediamine diaceturate promotes the release of active substances from platelets, enhances platelet aggregation and adhesion, and reduces capillary permeability to further control bleeding.

Brand names
朗好琪瑞弘远
Other names
diacetylaminoacetic acid ethylenediamineethylenediamine diaceturate for injectionethylenediamine diaceturate injection二乙酰氨乙酸乙二胺二乙酰氨乙酸乙二胺注射液注射用二乙酰氨乙酸乙二胺
02

Targets

PLG (Plasminogen)PLAU (uPA)PA (Influenza polymerase acidic protein)

Beyond the preview

Go deeper on ethylenediamine diaceturate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethylenediamine diaceturate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call